Imipenem/Cilastatine Steriscience

Imipenem, the active ingredient in Imipenem/Cilastatin Steriscience, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. Combined with cilastatin, it provides broad‑spectrum coverage against Gram‑negative, Gram‑positive and anaerobic bacteria in severe infections of hospitalized adults. It is indicated for a range of serious infections where rapid bactericidal activity is required.

GNH USA supplies Imipenem/Cilastatin Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with distribution across the European Union and other global markets.

Imipenem/Cilastatin is a carbapenem antibiotic used to treat severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves rapid bacterial eradication in the peritoneal cavity and reduces postoperative complications. - Complicated urinary tract infections: provides effective coverage of resistant Gram‑negative pathogens in the urinary tract. - Skin and soft‑tissue infections: eliminates mixed aerobic and anaerobic organisms in deep tissue infections. - Hospital‑acquired and ventilator‑associated pneumonia: delivers high lung tissue concentrations to treat resistant pneumonia. - Severe sepsis: offers broad‑spectrum bactericidal activity essential for systemic infection control.

Imipenem/Cilastatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools, sometimes leading to dehydration. - Vomiting: occasional emesis after infusion. - Rash: skin erythema or pruritus. - Headache: transient headache during therapy. - Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects: - Seizures: risk increased in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate discontinuation. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea. - Renal toxicity: acute kidney injury especially with concomitant nephrotoxic drugs. - Thrombophlebitis: inflammation at the intravenous site. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.

Before initiating Imipenem/Cilastatin, clinicians should consider several safety measures to minimize risks. - Assess renal function: adjust dosing or avoid use in severe renal impairment. - Monitor for seizures: especially in patients with a history of CNS disease. - Check for hypersensitivity: discontinue if rash, urticaria, or anaphylaxis develop. - Avoid concomitant valproic acid: may reduce valproate plasma levels and precipitate seizures. - Use aseptic technique: ensure sterile preparation and administration to prevent infection. - Store at below 25°C: keep in the original container, protect from moisture and light.

Imipenem/Cilastatin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: co‑administration markedly reduces valproate concentrations, risking seizure breakthrough. - CNS depressants (e.g., phenobarbital, carbamazepine): may lower seizure threshold when combined with imipenem. - Probenecid: can increase imipenem plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may enhance nephrotoxic potential; monitor renal function. - Anticoagulants (e.g., warfarin): imipenem may alter INR; check coagulation parameters. - Other nephrotoxic agents (e.g., aminoglycosides): increase risk of kidney injury; adjust dosing as needed.